Design Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Design Therapeutics, Inc. (DSGN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 17.44 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-03
- Design Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 17.39M shares, a 27.31% increase year-over-year.
- Design Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 13.66M shares, a 26.23% increase year-over-year.
- Design Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 10.82M shares, a 35.52% increase year-over-year.
- Design Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 7.99M shares, a 52.19% increase year-over-year.
- Design Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 10.40M shares, a 21.17% increase from fiscal 2023.
- Design Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.58M shares, a 57.42% increase from fiscal 2022.
- Design Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.45M shares, a 86.86% increase from fiscal 2021.
- Design Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 2.92M shares, a 81.48% decline from fiscal 2020.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 17.44M shares 10-Q · filed 2026-08-03 | |||||
| 2026-03-31 | 17.39M shares 10-Q · filed 2026-04-28 | |||||
| 2025-12-31 | 13.78M shares 10-Q · filed 2026-08-03 | |||||
| 2025-09-30 | 14.02M shares 10-Q · filed 2025-11-05 | |||||
| 2025-06-30 | 13.86M shares 10-Q · filed 2025-08-07 | |||||
| 2025-03-31 | 13.66M shares 10-Q · filed 2025-05-07 | |||||
| 2024-12-31 | 10.40M shares 10-K · filed 2026-03-09 | |||||
| 2024-09-30 | 10.77M shares 10-Q · filed 2025-11-05 | |||||
| 2024-06-30 | 10.74M shares 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | 10.82M shares 10-Q · filed 2024-05-08 | |||||
| 2023-12-31 | 8.58M shares 10-K · filed 2025-03-10 | |||||
| 2023-09-30 | 9.19M shares 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | 8.03M shares 10-Q · filed 2024-08-05 | |||||
| 2023-03-31 | 7.99M shares 10-Q · filed 2024-05-08 | |||||
| 2022-12-31 | 5.45M shares 10-K · filed 2024-03-19 | |||||
| 2022-09-30 | 5.35M shares 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | 5.41M shares 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | 5.25M shares 10-Q · filed 2023-05-09 | |||||
| 2021-12-31 | 2.92M shares 10-K · filed 2023-03-14 | |||||
| 2021-09-30 | 2.57M shares 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | 2.69M shares 10-Q · filed 2022-08-08 | 2.69M shares 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | 2.60M shares 10-Q · filed 2022-05-09 | 2.60M shares 10-Q · filed 2021-05-10 | ||||
| 2020-12-31 | 15.75M shares 10-K · filed 2022-03-10 | |||||
| 2020-09-30 | 14.46M shares 10-Q · filed 2021-11-09 | |||||
| 2020-06-30 | 14.43M shares 10-Q · filed 2021-08-09 | |||||
| 2020-03-31 | 14.51M shares 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |